An Investigator-Sponsored, Phase 1/2 trial of the oral XPO1 inhibitor selinexor (KPT-330) in combination with docetaxel for previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC)
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Study ID
Protocol Number: 18-0554
More information available at ClinicalTrials.gov: NCT03095612
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers